Titan Pharmaceuticals (NASDAQ:TTNP) and TC Biopharm (NASDAQ:TCBP) Financial Comparison

TC Biopharm (NASDAQ:TCBP) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Risk & Volatility

TC Biopharm has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.

Insider & Institutional Ownership

16.3% of TC Biopharm shares are owned by institutional investors. Comparatively, 31.5% of Titan Pharmaceuticals shares are owned by institutional investors. 15.4% of TC Biopharm shares are owned by company insiders. Comparatively, 24.9% of Titan Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares TC Biopharm and Titan Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TC Biopharm	N/A	N/A	N/A
Titan Pharmaceuticals	N/A	-99.96%	-77.58%

Analyst Recommendations

This is a summary of recent ratings and price targets for TC Biopharm and Titan Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TC Biopharm	0	0	0	0	N/A
Titan Pharmaceuticals	0	0	0	0	N/A

Earnings and Valuation

This table compares TC Biopharm and Titan Pharmaceuticals’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TC Biopharm	$4.76 million	0.88	-$7.35 million	N/A	N/A
Titan Pharmaceuticals	$180,000.00	24.67	-$5.57 million	N/A	N/A

Titan Pharmaceuticals has lower revenue, but higher earnings than TC Biopharm.

Summary

Titan Pharmaceuticals beats TC Biopharm on 5 of the 8 factors compared between the two stocks.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.